These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36882990)

  • 61. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
    Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
    Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
    [No Abstract]   [Full Text] [Related]  

  • 62. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
    Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
    Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.
    Saccaro S; Fonseca R; Veillon DM; Cotelingam J; Nordberg ML; Bredeson C; Glass J; Munker R
    Am J Hematol; 2005 Apr; 78(4):288-94. PubMed ID: 15795922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
    Mizuno S; Kitayama C; Mashiko S; Sanada S
    CEN Case Rep; 2022 May; 11(2):265-268. PubMed ID: 34817845
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
    Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
    [No Abstract]   [Full Text] [Related]  

  • 67. [Successful treatment of myelomatous pleural effusion with daratumumab administration before autologous peripheral stem cell transplantation].
    Wada A; Yasumura S; Kajikawa S; Murakami J; Sato T
    Rinsho Ketsueki; 2020; 61(8):879-884. PubMed ID: 32908050
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cooccurrence of classic Hodgkin lymphoma and multiple myeloma].
    Andoh S; Yokoyama K; Uchida S; Makiyama J; Kawamata T; Yasui H; Ota Y; Imai Y; Tojo A
    Rinsho Ketsueki; 2021; 62(1):14-19. PubMed ID: 33551419
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    Vincent Rajkumar S
    Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 72. What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
    Scott E; Reece D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():205-7. PubMed ID: 22160035
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
    J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Xanthoma-like Skin Changes in an Elderly Woman with a Normal Lipid Profile.
    Nockowski P; Woźniak Z; Reich A; Maj J
    Acta Dermatovenerol Croat; 2017 Jul; 25(2):167-169. PubMed ID: 28871936
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
    Ludwig H; Zojer N
    Nat Rev Clin Oncol; 2010 May; 7(5):289-94. PubMed ID: 20351701
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
    Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.